| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-011 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届监事会第十四次 会议通知于 2025 年 4 月 14 日以邮件形式发出，会议于 2025 年 4 月 24 日（星期 四）14:00-16:00 在上海市虹口区乍浦路 89 号星荟中心 1 座 8 楼公司会议室以现 场方式召开。会议应到监事 3 人，实到监事 3 人，公司董事会秘书张诚栩先生列 席了会议。会议由公司监事会主席严晨女士主持。 本次监事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 二、监事会会议审议情况 （一）审议通过了《2024年度监事会工作报告》。 报告期内 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-010 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海润达医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十 次会议通知于2025年4月14日以邮件形式发出，会议于2025年4月24日（星期四） 10:00-12:00在上海市虹口区乍浦路89号星荟中心1座8楼公司会议室以现场和通 讯相结合的方式召开。会议应到董事11人，实到董事11人（其中独立董事CHAN HWANG TONG因工作原因通讯参加会议），公司监事严晨、吴伟钟、丁秋泉和 高级管理人员廖上林列席了会议。会议由公司董事长张诚栩先生主持。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规和公司章程的规定，会议及通过的决议合 法有效。 二、董事会会议审议情 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-013 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次利润分配方案尚需提交股东大会审议。 二、公司不触及其他风险警示情形 重要内容提示： 分配比例：每 10 股派发现金红利 0.30 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股 分配比例不变，相应调整分配总额，并将在相关公告中披露。 本次不触及《上海证券交易所股票上市规则》第 9.8.1 条第一款第（八） 项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 众华会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，上海 润达医疗科技股份有限公司（以下简称"公司"）以合并报表口 ...

| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2025-016 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 关于全资子公司为公司发行公司债券提供反担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 反担保情况概述 为优化债务结构、降低融资成本，上海润达医疗科技股份有限公司（以下简 称"公司"）于 2024 年 6 月 27 日召开第五届董事会第十四次会议，会议审议通 过《关于注册公开发行公司债券的议案》，同意公司向中国证券监督管理委员会 申请注册总规模不超过人民币 10 亿元的公司债券。 反担保对象名称：兴农担保，非公司关联人。 本次担保金额及已实际为其提供的担保余额：杭州润达及惠中医疗本次 为兴农担保提供人民币 30,000 万元的反担保，截至本公告披露日未实际 为其提供担保。 本次担保是否有反担保：本次担保为反担保。 对外担保逾期的累计数量：无 特别风险提示：截至本公告披露日，公司 ...

上海润达医疗科技股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况的 专项说明 ZHONGHUA 上海润达医疗科技股份有限公司 2024年度 非经营性资金占用及其他关联资金往来情况 的专项说明 众会字(2025)第 05186号 上海润达医疗科技股份有限公司全体股东: 我们接受委托,依据《中国注册会计师执业准则》审计了上海润达医疗科技股份有限公 司(以下简称"润达医疗公司")2024年度的财务报表,包括 2024年12月31日的合并及公 司资产负债表,2024年度的合并及公司利润表、合并及公司现金流量表、合并所有者权益 变动表及公司所有者权益变动表以及财务报表附注,并于 2025年4月24日出具了众会字 (2025)第04148号《审计报告》。 根据中国证券监督管理委员会《上市公司监管指引第8号 -- 上市公司资金往来、对外 担保的监管要求》的要求以及参照上海证券交易所《上海证券交易所上市公司自律监管指南 第2号业务办理 -- 第六号定期报告》规定的非经营性资金占用及其他关联资金在来情况汇 总表格式,上海淘达医疗科技股份公司编制了后附的2024年度非经营性资金占用及其他关 联资金往来情况汇总表 ...

国金证券股份有限公司 关于上海润达医疗科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为上海润达医 疗科技股份有限公司（以下简称"润达医疗"或"公司"）公开发行可转换公司债券的 保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证券交易所股票上市规 则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》、《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》等有关规定，对润达 医疗 2024 年度募集资金存放与使用情况进行了审慎的核查，情况如下： 一、募集资金基本情况 （一）实际募集资金的数额、资金到位情况 根据公司 2019 年 2 月 27 日召开的第三届董事会第二十六次会议及公司 2019 年 3 月 18 日召开的 2019 年第一次临时股东大会决议，并经中国证券监督管理委员 会"证监许可[2020]586 号"《关于核准上海润达医疗科技股份有限公司公开发行可 转换公司债券的批复》核准，公司向社会公开发行可转换为公司 A 股股票的可转换 公司债券，债券票面金额为人民币 100.00 元， ...

上海润达医疗科技股份有限公司 2024 年度内部控制审计报告 一、润达医疗公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定，建立健全和有效实施内部控制，并评价其有效性是润达医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见， 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控制审计结 果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 众会字（2025）第 05185 号 上海润达医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了上 海润达医疗科技股份有限公司（以下简称"润达医疗公司"）2024 年 12 月 31 日的财务报告 内部控制的有效性。 四、财务报告内部控制审计意见 我们认为，上海润达医疗科技股份有限公司于 2024 年 12 月 ...

上海润达医疗科技股份有限公司 2024 年度 财务报表及审计报告 目录 | | 内容 | 页码 | | --- | --- | --- | | 审计报告 | | | | 合并资产负债表 | | 1-2 | | 公司资产负债表 | | 3-4 | | 合并利润表 | | 5 | | 公司利润表 | | 6 | | 合并现金流量表 | | 7 | | 公司现金流量表 | | 8 | | 合并所有者权益变动表 | | 9-10 | | 公司所有者权益变动表 | | 11-12 | | 财务报表附注 | | 15-194 | 审计报告 众会字(2025)第 04148 号 上海润达医疗科技股份有限公司全体股东： 一、审计意见 我们审计了上海润达医疗科技股份有限公司（以下简称"润达医疗公司"）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公司现金流量表、合并及公司 股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了润达医疗公司 2024 年 12 月 31 日的合并及公司财务状况以及 202 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,661,846,010.13, a decrease of 19.81% compared to ¥2,072,478,429.77 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥69,258,725.43, representing a decline of 406.40% from a profit of ¥22,603,808.03 in the previous year[4] - The basic earnings per share decreased to -¥0.11, down 375.00% from ¥0.04 in the same period last year[4] - Net profit for Q1 2025 was a loss of ¥67,863,002.26, compared to a profit of ¥47,521,987.16 in Q1 2024[17] - The total equity attributable to shareholders was ¥4,285,970,376.96 in Q1 2025, down from ¥4,354,582,007.41 in Q1 2024[14] - The company's total equity decreased to CNY 2,798,647,234.17 from CNY 2,803,495,366.03, a decline of approximately 0.2%[25] - The total comprehensive income for the period was -4,976,211.79 RMB, compared to -5,573,183.84 RMB in the prior year[26] Cash Flow - The cash flow from operating activities showed a significant improvement, with a net cash flow of ¥116,669,541.90, compared to a negative cash flow of -¥40,845,966.27 in the previous year, marking a 385.63% increase[4] - Cash inflow from operating activities was ¥2,103,042,784.86 in Q1 2025, compared to ¥2,219,850,447.83 in Q1 2024, reflecting a decrease of 5.2%[19] - The net cash flow from operating activities was -25,319,918.73 RMB, compared to -192,986,266.99 RMB in the same period last year, showing a significant reduction in cash outflow[30] - The company's cash and cash equivalents decreased to ¥945,817,244.30 from ¥1,206,525,197.67, representing a decline of about 21.56%[12] - The company's cash and cash equivalents at the end of the period were CNY 682,194,527.34, down from CNY 611,884,719.64, showing a net decrease of CNY 206,870,757.77[20] - Cash inflow from financing activities was 874,205,838.66 RMB, while cash outflow was 993,315,410.14 RMB, leading to a net cash flow of -119,109,571.48 RMB from financing[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥14,039,401,555.19, a decrease of 1.86% from ¥14,305,542,661.54 at the end of the previous year[5] - The total current assets decreased to CNY 3,350,867,336.73 from CNY 3,655,433,459.03, reflecting a decline of approximately 8.3%[23] - The total liabilities decreased to ¥9,174,000,000.00 from ¥9,500,000,000.00, reflecting a reduction of approximately 3.43%[12] - The company's total liabilities decreased to CNY 5,736,728,905.55 from CNY 6,041,694,331.77, indicating a reduction of about 5.0%[24] - The company's long-term borrowings increased to ¥787,127,257.71 in Q1 2025 from ¥661,578,715.54 in Q1 2024, representing a growth of 18.9%[14] - The company's long-term equity investments rose to ¥1,465,506,304.57 from ¥1,442,616,370.31, an increase of about 1.59%[12] Operational Challenges - The gross profit margin decreased by approximately 6% compared to the same period last year, leading to a total gross profit reduction of ¥210 million[7] - The company faced challenges due to price reductions in certain regions, impacting revenue and profit margins significantly[7] - The company is focusing on controlling costs and expenses to adapt to market changes despite the revenue decline[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 75,979[9] Other Financial Metrics - The weighted average return on equity was -1.60%, a decrease of 2.13 percentage points compared to 0.53% in the previous year[5] - The company's financial expenses for Q1 2025 were CNY 34,256,843.36, down from CNY 41,420,105.76 in Q1 2024, reflecting a decrease of approximately 17.4%[25] - The company's goodwill remained stable at ¥1,982,679,226.06, unchanged from the previous period[12] - The total non-current assets slightly decreased to ¥5,094,706,515.56 from ¥5,102,522,533.62, indicating a minor decline of approximately 0.15%[12] - The company's other comprehensive income after tax for Q1 2025 was ¥61,323.97, compared to ¥1,025,645.62 in Q1 2024[18] - The company reported an investment income of CNY 81,856,466.19 for Q1 2025, significantly higher than CNY 24,883,601.31 in Q1 2024, marking an increase of approximately 228.5%[25] Accounting Standards - The company is not applying new accounting standards or interpretations starting from 2025[32]

Financial Performance - The company's operating revenue for 2024 was CNY 8,311,780,357.39, a decrease of 9.13% compared to CNY 9,147,372,720.28 in 2023[23]. - The net profit attributable to shareholders for 2024 was CNY 55,280,607.97, down 79.77% from CNY 273,296,495.22 in 2023[23]. - The basic earnings per share for 2024 was CNY 0.09, reflecting an 80.85% decrease from CNY 0.47 in 2023[24]. - The total assets at the end of 2024 were CNY 14,305,542,661.54, a slight decrease of 0.03% from CNY 14,309,993,279.77 in 2023[24]. - The net cash flow from operating activities for 2024 was CNY 646,947,379.71, down 11.34% from CNY 729,722,791.55 in 2023[23]. - The company reported a significant decline in net profit due to the impact of domestic macroeconomic conditions and price reductions in diagnostic products[24]. - The weighted average return on equity for 2024 was 1.29%, a decrease of 5.55 percentage points from 6.84% in 2023[24]. - The company's gross margin slightly decreased due to the impact of medical policy environment changes[49]. - The company achieved operating revenue of 8.312 billion RMB, a decrease of 9.13% compared to the same period last year[34]. - The net profit attributable to shareholders was 55.2806 million RMB, down 79.77% year-on-year[34]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 0.30 yuan per 10 shares to all shareholders, based on the total share capital as of the dividend distribution date[6]. - The company aims to allocate at least 20% of its distributable profits as cash dividends annually, provided the operating environment remains stable[171]. - The cash dividend amount (including tax) is CNY 18,109,208.37, which accounts for 32.76% of the net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements[175]. - The cumulative cash dividend amount over the last three accounting years (including tax) is CNY 164,941,391.63, with an average annual net profit of CNY 249,419,699.54, resulting in a cash dividend ratio of 66.13%[178]. - The company has outlined a three-year dividend return plan for shareholders covering the years 2024 to 2026[145]. Corporate Governance and Management - The company has received a standard unqualified audit report from Zhonghua Certified Public Accountants[5]. - The company’s financial report has been confirmed as true, accurate, and complete by its responsible personnel[5]. - The company’s board of directors and supervisory board members have all attended the board meeting[4]. - The company held its annual general meeting on May 23, 2024, where several key resolutions were approved, including the 2023 annual financial report and the profit distribution plan for 2023[145]. - The total remuneration for directors and senior management during the reporting period amounted to 907.25 million yuan[147]. - The company has not reported any significant changes in the competitive landscape or measures taken to address potential conflicts of interest with controlling shareholders[145]. - The company has a structured compensation policy that combines fixed salaries with performance-based incentives[167]. - The company has established a performance management system that combines regular and irregular assessments to determine employee compensation and bonuses[189]. Market and Competitive Landscape - The company is a leading comprehensive service provider for medical laboratories, leveraging big data and AI to support various laboratory operations, including in vitro diagnostic products and technical services[72]. - The company faces intensified market competition in the in vitro diagnostic product sector, with increased investment from competitors leading to higher competitive risks[138]. - The domestic public hospital testing revenue reached CNY 452 billion in 2022, with a year-on-year growth of 10.4%[66]. - The IVD intermediary service market is estimated to be around CNY 1,500-1,800 billion, showing stable growth[66]. - The industry concentration has increased, with the top 10 companies' market share rising from 15% in 2021 to 28% in 2023[68]. Research and Development - The company invested 116 million RMB in R&D, maintaining high levels of investment in IVD products and digital information systems[45]. - The company has developed a series of digital information products, including the SIMS system and the Mai47 system, to support laboratory management and clinical decision-making[84]. - The company is actively integrating AI technology into its services, creating new profit points and expanding its market presence[87]. - The company has launched new products in the glycosylated hemoglobin detection market, including MQ-3000, MQ-2000T, MQ-6000, and MQ-8000, maintaining a leading position domestically[56]. - The company is focusing on AI-assisted management to reduce waste and improve efficiency in laboratory operations, such as inventory forecasting and preventive maintenance[73]. Strategic Initiatives - The company plans to focus on improving operational efficiency and exploring new market opportunities to recover from the current downturn[24]. - The company aims to enhance its service platform and expand its market presence by focusing on centralized and regional testing center businesses[132]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[148]. - The company is considering strategic acquisitions to bolster its product offerings, with a budget of $100 million allocated for potential deals[149]. - The company is adopting a group management model for subsidiaries to standardize core business operations, aiming for efficient operations and improved synergy[136]. Social Responsibility and Sustainability - The company has invested CNY 220,000 in environmental protection during the reporting period[184]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[185]. - The total investment in social responsibility projects is CNY 2,351,000, including CNY 2,167,500 for scholarships and charitable funds[188]. - The company actively participates in public welfare activities, contributing to education and public health initiatives, thereby fulfilling its social responsibility[190]. - The company has maintained a record of zero accidents in production safety throughout the year, focusing on energy conservation and reducing environmental pollution as part of its sustainable development strategy[189].